UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCER
- 1 July 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 174 (1), 14-20
- https://doi.org/10.1097/01.ju.0000162039.38023.5f
Abstract
Recent years have seen several advances in the treatment of locally advanced and metastatic bladder cancer. We summarize the current state of the art for advanced bladder cancer treatment. A comprehensive review of published, prospective phase II/III clinical trials and retrospective analyses of patients with advanced bladder cancer was performed. Adjuvant and neoadjuvant chemotherapeutic strategies around the time of radical cystectomy have been used to decrease the risk of subsequent metastatic disease. Although the benefit of adjuvant chemotherapy remains unproven, neoadjuvant chemotherapy is associated with a modest 5% to 6% absolute survival benefit in 2 meta-analyses of the available data. Chemoradiation is feasible and effective in some patients, allowing bladder preservation with an acceptable risk of progression. Randomized, phase III data comparing methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy to gemcitabine/cisplatin showed similar response proportions and overall survival with less toxicity in the gemcitabine/cisplatin arm. This has led to the widespread use of gemcitabine/cisplatin as first line chemotherapy for metastatic bladder cancer. The optimal agents and regimens for second line chemotherapy remain undefined. Similarly biological and targeted therapies for advanced bladder cancer remain investigational. Combination cisplatin based neoadjuvant chemotherapy may benefit patients with locally advanced bladder cancer. Gemcitabine/cisplatin has replaced methotrexate, vinblastine, doxorubicin and cisplatin as the regimen of choice in patients with good renal function. The optimal regimens for the medically unfit patient and second line chemotherapy remain undefined. The development of targeted therapies, less toxic regimens and improved cytotoxic agents are necessary to improve outcomes.Keywords
This publication has 43 references indexed in Scilit:
- Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group ReportJournal of Clinical Oncology, 2004
- The evolving role of pelvic lymphadenectomy in the treatment of bladder cancerUrologic Oncology: Seminars and Original Investigations, 2004
- Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomyCancer, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?Annals Of Oncology, 2002
- Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VACJournal of Clinical Oncology, 2001
- The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year OutcomeJournal of Urology, 1997
- Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III StudyJournal of Urology, 1995
- Neoadjuvant Chemotherapy in Bladder Cancer: A Randomized StudyScandinavian Journal of Urology and Nephrology, 1993
- Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the BladderBritish Journal of Urology, 1991